Nichols Martin
GeoVax Labs has partnered with Leidos on an effort to develop anti-malaria vaccines in support of the United States Agency for International Development.
The companies will work to deliver vaccine candidates that combat P. falciparum malaria under USAID's Malaria Vaccine Development Program, GeoVax said Monday.
Under the partnership, GeoVax will offer its technology built on Modified Vaccinia Ankara, a platform that produces multimeric proteins as vaccine antigens.
Farshad Guirakhoo, chief scientific officer at GeoVax, said the firm's vaccine technology works to deliver multiple transgenes that overcome limitations of protein-derived and vector-derived vaccines.
